论文部分内容阅读
目的:分析我国《国家基本药物目录》(2012年版)药品儿童用药信息情况,为进一步完善我国儿童用药政策提供相关建议。方法:收集最新版本的《国家基本药物目录》(2012年版)药品说明书,提取儿童用药信息,采用Excel 2007软件进行数据统计分析。结果:《国家基本药物目录》(2012年版)按展开剂型计算:37.08%有儿童用法用量,3.37%有新生儿用法用量,1.61%有早产儿用法用量,7.38%涉及儿童的药动学数据,10.59%禁用于各年龄段儿童。无儿童用法用量的药品按品种名称通过Micromedex数据库检索,37.73%的药品涵盖的全部给药途径均有儿童用法用量,4.19%的药品涵盖全部给药途径均有新生儿用法用量,3.59%有早产儿用法用量,19.76%涉及儿童药动学数据。结论:《国家基本药物目录》(2012年版)化学药品和生物制品中儿童用药信息仍较缺乏,儿童药动学数据很少。建议我国进一步完善儿童用药政策。
OBJECTIVE: To analyze the information on drug use and drug information of “National Essential Drugs List” (2012 Edition) in China, and provide suggestions for further improving our children’s drug policy. Methods: Collect the latest version of the “National Essential Drug List” (2012 version) drug specification, extract information on children’s medication, using Excel 2007 software for statistical analysis of data. Results: The National Essential Drugs Inventory (2012 Edition) was calculated on a spread of dosage forms: 37.08% had children’s usage, 3.37% had newborns, 1.61% had preterm infants, 7.38% had children’s pharmacokinetic data, 10.59% Disabled for children of all ages. Drugs with no usage of children were searched by Micromedex database according to the name of the product. 37.73% of the drugs covered all the usage of children, 4.19% of the drugs covered the whole dosage of neonatal usage, 3.59% had the preterm birth Pediatric dosage, 19.76% involving children pharmacokinetic data. Conclusion: There is still a lack of information on pediatric drug use in the “National Essential Drugs Inventory” (2012 edition) for pediatric drugs and biologics, with little pediatric pharmacokinetic data. Suggest that China further improve the policy of children’s medication.